TheraRadar
← Back
Data updated: Jun 28, 2026

EISAI MEDCL RES

Pharma
Infectious DiseaseGastroenterology Execution: Excellent

EISAI MEDCL RES is a pharmaceutical company focused on Infectious Disease, Gastroenterology.

2002
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

EISAI MEDCL RES at a Glance

  • Strong track record with 93% execution quality across 106 trials
  • Fast trial execution (25 months median completion)

EISAI MEDCL RES's Key Drugs

EISAI MEDCL RES's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

EISAI MEDCL RES's Recent FDA Approvals

New NDA/BLA approvals for EISAI MEDCL RES over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

EISAI MEDCL RES's Therapeutic Areas

EISAI MEDCL RES's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 50%
1 drugs
Gastroenterology 50%
1 drugs

EISAI MEDCL RES's Top Competitors

EISAI MEDCL RES's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Infectious Disease, Gastroenterology
Bristol-Myers Squibb big-pharma
Infectious Disease, Gastroenterology
APOTHECON specialty
Infectious Disease, Gastroenterology
PF PRISM CV big-pharma
Infectious Disease, Gastroenterology
ASTELLAS specialty
Gastroenterology, Infectious Disease

EISAI MEDCL RES Pipeline Snapshot

Active clinical trials for EISAI MEDCL RES across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 17/18 completed
  • • Speed: 25 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges